Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Changing treatment news

Show

From To
People with HIV and hepatitis B co-infection can safely switch to simpler TAF single-tablet regimen

People with HIV and hepatitis B virus (HBV) co-infection maintained HIV viral suppression, maintained or achieved HBV suppression and showed improvements in kidney and bone markers when

Published
18 August 2015
By
Liz Highleyman
Pretreatment HIV drug resistance leads patients to switch to second-line ART

Recent data suggested that retreatment HIV drug resistance in sub-Saharan Africa was associated with a nearly fourfold increase in switching to second-line ART, but did not influence mortality or AIDS-related events.

Published
11 August 2015
From
Healio
HIV-positive patients in Africa do well on three second-line ART regimens

Three second-line antiretroviral therapy (ART) regimens are equally safe and effective for patients experiencing virological failure in Africa, investigators report in the online study of AIDS. All three regimens

Published
16 July 2015
By
Michael Carter
Second-line ART patients reach viral re-suppression following intensified adherence support

Sixty-seven per cent of all patients who were experiencing treatment failure on second-line antiretroviral therapy (ART) achieved viral re-suppression after intensified adherence support was provided, according

Published
13 July 2015
By
Lesley Odendal
High treatment failure rate among Thai children switching to second-line ART

There is a high treatment failure rate among children taking second-line antiretroviral therapy (ART), Thai investigators report in the online edition of Clinical Infectious Diseases. Therapy was

Published
20 April 2015
By
Michael Carter
Dolutegravir and Truimeq approved in England: London guidelines updated

On 14 January 2015, NHS England published the long awaited policy on dolutegravir and the fixed dose combination (FDC) of dolutegravir/abacavir/3TC (Triumeq). The London prescribing guidelines for first-line therapy have also been updated to include dolutegravir and Triumeq.

Published
14 January 2015
From
HIV i-Base
Sophisticated HIV diagnostics adapted for remote areas

Diagnosing HIV and other infectious diseases presents unique challenges in remote locations that lack electric power, refrigeration, and appropriately trained health care staff. To address these issues, researchers have developed a low-cost, electricity-free device capable of detecting the DNA of infectious pathogens, including HIV-1.

Published
10 December 2014
From
Science Daily
Protease inhibitor monotherapy: darunavir/ritonavir less effective than three-drug therapy

Darunavir/ritonavir monotherapy results in a lower rate of viral suppression after 48 weeks when compared to darunavir/ritonavir plus two nucleoside reverse transcriptase inhibitors (NRTIs), but may

Published
07 November 2014
By
Keith Alcorn
Do emtricitabine and lamivudine have similar virological efficacy when used in first-line HIV therapy?

First-line antiretroviral regimens containing emtricitabine have superior virological efficacy to combinations containing lamivudine when combined with tenofovir and either nevirapine or efavirenz, Dutch investigators report in the online

Published
03 November 2014
By
Michael Carter
Effective treatments available for HIV patients not eligible for efavirenz regimens

HIV drug regimens that do not include efavirenz are effective as first-line antiretroviral therapy, a new American clinical trial found. The finding is important for patients who are not eligible for treatment with efavirenz, including women considering becoming pregnant and patients with a history of severe psychiatric disorders.

Published
07 October 2014
From
Science Daily
← First12345...24Next →

Filter by country